Resources:
On 21 September 2022, the RWE4Decisions community gathered for a multi-stakeholder discussion on HealthData in Germany, with a focus on the routine data collection practice (AbD) at the Federal Joint Committee (G-BA). The panel featured representation of HTA bodies, patients, insurers and industry.
President of the Commission of Drugs Reimbursement, National Institute of Health and Disability Insurance (INAMI-RIZIV), Belgium
Evidence Based Health Policy Consultant, RWE4Decisions Secretariat
Head of Pharmaceuticals Department, German Federal Joint Committee (G-BA)
Head of Pharmaceuticals Department, German Federal Joint Committee (G-BA)
Managing Director, Federal Association of Self-Help Organisations for people with disabilities and chronic diseases and their relatives (BAG Selbsthilfe)
Head of Pharmaceuticals, Society for efficiency and quality in health insurance companies (GWQ ServicePlus AG)
Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
President of the Commission of Drugs Reimbursement, National Institute of Health and Disability Insurance (INAMI-RIZIV), Belgium
This was the second public webinar to update on how countries are developing their data environments in a way that could be useful for HTA bodies and Payers, to support additional data collection.
Public Webinar: From Policy to Practice: EHDS Implementation to Support Better Real-World Evidence for HTA/Payers
RWE4Decisions Symposium: Developing Real-World Evidence to Deliver Innovation in HTA
Public Webinar: HTA/Payer Collaboration in the Nordics: The Role of Real-World Evidence
